SomnoMed Limited
SOMNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $58 | $54 | $47 | $45 |
| % Growth | 7.6% | 15.4% | 3.2% | – |
| Cost of Goods Sold | $24 | $21 | $22 | $20 |
| Gross Profit | $34 | $33 | $24 | $25 |
| % Margin | 58.2% | 61.6% | 52% | 54.6% |
| R&D Expenses | $1 | $1 | $0 | $1 |
| G&A Expenses | $11 | $9 | $9 | $9 |
| SG&A Expenses | $33 | $29 | $28 | $29 |
| Sales & Mktg Exp. | $12 | $11 | $12 | $14 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34 | $29 | $28 | $29 |
| Operating Income | -$0 | $4 | -$4 | -$4 |
| % Margin | -0% | 6.8% | -9.3% | -8.9% |
| Other Income/Exp. Net | -$2 | -$2 | -$1 | -$2 |
| Pre-Tax Income | -$2 | $2 | -$6 | -$6 |
| Tax Expense | $1 | $2 | $0 | $1 |
| Net Income | -$3 | -$0 | -$6 | -$6 |
| % Margin | -5.8% | -0.2% | -12.7% | -14.1% |
| EPS | -0.016 | -0.001 | -0.049 | -0.053 |
| % Growth | -1,644.4% | 98.2% | 7% | – |
| EPS Diluted | -0.016 | -0.001 | -0.049 | -0.053 |
| Weighted Avg Shares Out | 213 | 121 | 121 | 121 |
| Weighted Avg Shares Out Dil | 213 | 121 | 121 | 121 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $1 |
| Depreciation & Amortization | $0 | $2 | $3 | $3 |
| EBITDA | -$1 | $3 | -$2 | -$1 |
| % Margin | -2.6% | 5.7% | -3.5% | -2.5% |